- Cavallari I*, Cerciello F*, Giovannetti E*, Urso L*, “Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets, Front Oncol. 2023 Mar 6;13:1163144. doi: 10.3389/fonc.2023.1163144. eCollection 2023. (* equal contributors)
- Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau JF, Jean D, Felley-Bosco E, “Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma”, JTO Clin Res Rep. 2022 Nov 7;3(12):100430. doi: 10.1016/j.jtocrr.2022.100430. PMID: 36467966; PMCID: PMC9709230.
- Kündig A, Zens P, Fung C, Scherz A, Cerciello F, Herrmann E, Ermis E, Schmid RA, Vassella E, Berezowska S, “PD-L1 expression in lung cancer and paired brain metastases– a single center study in 190 patients, JTO Clinical and Research Reports (2022), doi.org/10.1016/j.jtocrr.2022.100413.
- Martens M, Kreidl F, Ehrhart F, Jean D, Mei M, Mortensen MM, Nash A, Nymark P, Evelo CT, Cerciello F, “A Community-Driven, Openly Accessible Molecular Pathway Integrating Knowledge on Malignant Pleural Mesothelioma”, Front. Oncol. 2022, 12:849640, doi: 10.3389/fonc.2022.849640
- Cerciello F, Choi M, Sinicropi-Yao SL, Lomeo K, Amann JM, Felley-Bosco E, Stahel RA, Robinson B, Creaney J, Pass HI, Vitek O, Carbone DP, “Verification of a blood based targeted proteomics signature for malignant pleural mesothelioma”, Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):1973-1982. doi: 10.1158/1055-9965.EPI-20-0543. Epub 2020 Jul 30.
For a complete list of publications follow this URL: https://www.ncbi.nlm.nih.gov/myncbi/1fsdls7zOtjk9/bibliography/public/
